TI-0032 induces B-cell depletion in preclinical setting
AI Briefing
- • TI-0032 is an anti-CD19 CAR circular RNA therapeutic developed by Therorna Shanghai Co. Ltd.
- • The treatment is delivered via lipid nanoparticles (LNPs) for autoimmune and hematological disorders.
- • TI-0032 induces B-cell depletion in a preclinical setting.
Source Summary
Therorna Shanghai Co. Ltd. has presented data on TI-0032, an anti-CD19 CAR circular RNA therapeutic delivered by lipid nanoparticles (LNPs) for the treatment of autoimmune and hematological disorders.
Advertisement